BlossomHill Therapeutics — Second Quarter 2026 Earnings Summary

Financial Performance

• Research and development expenses for Q2 2026 were $21.4 million, up from $12.5 million in Q2 2025, driven by increased clinical development costs for the SOLARA trial, IND-enabling studies for BH-501284, and higher personnel and overhead costs.
• General and administrative expenses for Q2 2026 were $3.3 million, compared to $1.6 million in Q2 2025, due to increased legal, personnel, and overhead expenses.
• Net loss for Q2 2026 was $23.8 million ($8.75 per basic and diluted share), compared to a net loss of $13.2 million ($5.51 per basic and diluted share) in Q2 2025.
• Cash and cash equivalents totaled $95.4 million as of June 30, 2026, down from $136.7 million as of December 31, 2025.
• The company completed an IPO in August 2026, selling 10,516,240 shares for gross proceeds of $168.3 million.
• Management states that cash and cash equivalents as of June 30, 2026, combined with IPO proceeds, are sufficient to fund operations into Q2 2028.

Guidance and Future Outlook

• BH-30643: An End-of-Phase 1 meeting is anticipated in Q4 2026 regarding recommended Phase 2 dose selection and a potential accelerated approval pathway for C797S resistance. The first patient is expected to be dosed in a pivotal Phase 2 trial in Q1 2027. Updated Phase 1 data including C797S durability is expected in H1 2027, with updated Phase 1 data on TKI-naive durability and initial chemo combo cohort data expected in H2 2027.
• BH-501284: An Investigational New Drug (IND) submission is anticipated in Q1 2027.
• BH-30236: Updated Phase 1 data on safety and anti-leukemic effects is expected in H1 2027.

Business Segments and Product Lines

• BH-30643: Received FDA Fast Track designation for the treatment of advanced or metastatic EGFR C797S-positive NSCLC after prior treatment with a third-generation EGFR TKI. Preliminary data from the SOLARA trial presented at ASCO 2026 showed a 45% objective response rate and 88% disease control rate in patients with C797S resistance to prior TKIs.
• BH-501284: First preclinical data presented at AACR 2026 demonstrated sustained target engagement leading to tumor regression at low dose levels using a novel pseudo-irreversible pan-KRAS inhibitor scaffold.
• BH-30236: Initial clinical data presented at EHA 2026 showed encouraging safety and early signs of anti-leukemic activity as a monotherapy and in combination with venetoclax in relapsed or refractory AML and higher-risk MDS. The FDA has granted orphan drug designation for BH-30236 for the treatment of AML.

Other Key Points

• The company expanded its Board of Directors with the appointments of Sheila Gujrathi, M.D., and John Schmid.
• BlossomHill Therapeutics is a clinical-stage biopharmaceutical company focused on innovative small molecule medicines for cancer treatment.
• The SOLARA trial is a global Phase 1/2 first-in-human clinical trial spanning more than 40 sites in 10 countries.
• BH-30643 is designed to overcome limitations of currently approved EGFR inhibitors, showing potent activity across classical, on-target resistance (C797S with or without T790M), atypical, and exon 20 insertion mutations.
• BH-30236 targets aberrant alternative splicing machinery in R/R AML and HR-MDS, which cancer cells exploit to develop resistance to venetoclax, FLT3 inhibitors, and cytarabine.
• BH-501284 utilizes a non-covalent Switch-II chemical scaffold to achieve "pseudo-irreversible" binding with high affinity and selectivity for KRAS.